Early use of chemotherapy in metastatic prostate cancer

Markowski, Mark C.; Carducci, Michael A.

doi:10.1016/j.ctrv.2016.09.017

Cited by 21 publications

(19 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies reporting the use of docetaxel in metastatic hormone-sensitive prostate cancer have led to a change in clinical practice, with docetaxel being administered with ADT earlier. 12 , 19 , 20 This paradigm change may lead to a refinement in the sequencing of docetaxel. However, this change may potentially result in more patients’ cancer becoming resistant to docetaxel at the time of progression to mCRPC.…”

Section: Discussionmentioning

confidence: 99%

“… 11 Several retrospective studies provide little guidance on the optimal sequencing of agents. 12 Two ongoing studies ( ClinicalTrials.gov identifiers: NCT02125357 and NCT02485691) are assessing treatment sequencing in mCRPC, with completion scheduled for 2018. Meanwhile, observational patient registries report real-world clinical outcomes and are an invaluable source of information on health care services, disparities in access to treatment, quality of care, and other factors affecting treatment decisions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Akaza

Procopio

Pripatnanont

et al. 2018

JGO

View full text Add to dashboard Cite

PurposeThere is a major clinical need to devise an optimal treatment sequence for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, sequencing information can be derived from large, real-world registry studies.Patients and MethodsPROXIMA (Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy) is a large, global, prospective registry study evaluating real-world treatment patterns of patients with mCRPC who experience disease progression during or after docetaxel therapy. Patients were enrolled worldwide between 2011 and 2014. Treatments were determined by the treating physicians and recorded in categories of chemotherapy, hormonal therapy, targeted therapy, immunotherapy, and palliative therapy. Treatment sequencing patterns, response to treatment, and types of progression were recorded and analyzed. Progression-free survival and overall survival with different treatment modalities were analyzed using Kaplan–Meier method.ResultsTreatment patterns were evaluated in 903 patients. Therapy selection was influenced by region. Hormonal therapy (57.5%) and taxane chemotherapy (26.4%) were the most frequently administered first subsequent treatments after docetaxel. Tumor responses to first subsequent treatment were observed in 22.6% of evaluable patients. Overall survival and progression-free survival did not differ significantly across different treatment modalities.ConclusionIdentifying an optimal treatment sequence is vital for improving the care of patients with mCRPC. The PROXIMA registry provided a representative sample of global data on real-world treatment patterns for patients with mCRPC previously treated with docetaxel. These data can be used to devise optimal therapy sequences and inform treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Akaza

Procopio

Pripatnanont

et al. 2018

JGO

View full text Add to dashboard Cite

show abstract

“…However, nearly all mPCa patients will eventually progress to castration-resistant status. Although novel medicine like enzalutamide and systematic chemotherapy regimens had made great progress in treating mPCa, especially mCRPC patients, it was still far from ideal condition 33 , 34 . Recently, some research groups focused on whether definitive treatment of the primary tumor can improve the prognosis of mPCa patients.…”

Section: Discussionmentioning

confidence: 99%

“…To date, androgen-deprivation therapy (ADT) is the gold-standard therapy for advanced PCa patients 6 . Although response rates to ADT are almost 80%, most patients will eventually progress to castration-resistant status, which is accompanied by poor outcome and high lethality 7 , 8 . Therefore, knowledge of novel biomarkers for predicting prognosis of mPCa is of great importance and interest.…”

Section: Introductionmentioning

confidence: 99%

Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status

Guo

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

T cell immunoglobulin 3 (TIM3) is a cell surface star molecule expressed on T cells, and also marks dysfunctional CD8+ T cells in various kinds of cancers. However, there are few studies focusing on the expression of TIM3 in tumor cells. In our study, we recruited 139 patients with metastatic prostate cancer (mPCa) who received transurethral resection of the prostate (TURP) consecutively to examine whether TIM3 expression level is associated with overall survival (OS) in mPCa patients. Immunohistochemistry was performed to determine TIM3 expression in prostate cancer tissues and then patients were divided into two groups. In multivariate Cox analysis, we revealed that mPCa patients with negative TIM3 expression, younger age, no radiotherapy, higher Gleason score, higher cT stage and patients of mCRPC had a shorter OS. Therefore, a predictive nomogram was generated with identified independent prognostic factors to assess patients’ OS at 3 years. Multivariate logistic regression revealed that higher cT stage, higher Gleason score and low TIM3 expression were independent predictors of metastatic castration resistant prostate cancer (mCRPC). In conclusion, low expression level of TIM3 in prostate cancer tissues is an independent prognostic factor of poor prognosis for mPCa patients, and also an independent predictor of mCRPC.

show abstract

“…There are direct causal relationships between such molecular changes and therapeutic impairment or failure of drugs targeting these pathways (10). Several studies are therefore ongoing to test whether such substances could be more active in a hormone-naïve setting (11). …”

mentioning

confidence: 99%

Treatment of metastatic prostate cancer after STAMPEDE

Wolf

2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

Early use of chemotherapy in metastatic prostate cancer

Cited by 21 publications

References 63 publications

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status

Treatment of metastatic prostate cancer after STAMPEDE

Contact Info

Product

Resources

About